BioMark Diagnostics Inc. and Rubix LS jointly announce the signature of a strategic partnership to develop better diagnostic tools to enhance lung cancer screening and improve breast cancer screening program, especially for women with dense breasts and Triple Negative Breast Cancer (TNBC), by focusing on reaching underserved communities. This collaboration combines the innovative strengths of both organizations to develop accessible, non-invasive, and accurate diagnostic solutions that promise to set new standards in early detection and personalised cancer treatment. Breast and lung cancers are among the leading health challenges for women worldwide, with early detection being crucial for successful treatment outcomes.

However, access to early screening and diagnostics remains a significant barrier, particularly in underserved communities. Recognizing this, Rubix LS and BioMark are dedicating their partnership to advancing cancer detection technologies and ensuring these innovations reach those most in need. The initiative will harness Rubix LS's strength as a culturally competent research catalyst, with CLIA/CAP clinical laboratory capacity to perform screening and conducting necessary clinical studies working in harmony with BioMark's expertise in translating blood-based biomarker research into laboratory-developed diagnostic tests (LDT) that are not only effective but also widely accessible.

Central to this effort is the deployment of mobile diagnostics and telehealth services, meticulously designed to bridge the gap in healthcare access and extend advanced cancer screening technologies to remote and underserved communities. This approach underscores a commitment to equity, ensuring that healthcare solutions reach all segments of the population, particularly those in areas traditionally neglected by advancements in medical technology. This initiative to transform women's health is a call to action for the healthcare community to prioritize equity in access to preventive care and to invest in solutions that can reach and benefit all populations, especially those historically marginalized or overlooked.

Rubix LS and BioMark is proud to lead this charge, aiming to inspire a global movement towards more inclusive healthcare practices.